ES2645022T3 - Dispositivo de extracción de sangre que contiene inhibidor de lisofosfolipasa - Google Patents
Dispositivo de extracción de sangre que contiene inhibidor de lisofosfolipasa Download PDFInfo
- Publication number
- ES2645022T3 ES2645022T3 ES12709440.7T ES12709440T ES2645022T3 ES 2645022 T3 ES2645022 T3 ES 2645022T3 ES 12709440 T ES12709440 T ES 12709440T ES 2645022 T3 ES2645022 T3 ES 2645022T3
- Authority
- ES
- Spain
- Prior art keywords
- inhibitor
- cetonomethyl
- blood
- tetrahydroacridine
- ghrelin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004369 blood Anatomy 0.000 title claims description 75
- 239000008280 blood Substances 0.000 title claims description 75
- 239000003112 inhibitor Substances 0.000 title claims description 51
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 title claims description 8
- 108020002496 Lysophospholipase Proteins 0.000 title claims description 8
- -1 n-dodecyl Chemical group 0.000 claims description 40
- 239000003381 stabilizer Substances 0.000 claims description 32
- 101800001586 Ghrelin Proteins 0.000 claims description 30
- 102400000442 Ghrelin-28 Human genes 0.000 claims description 29
- 238000000605 extraction Methods 0.000 claims description 26
- 229940002612 prodrug Drugs 0.000 claims description 21
- 239000000651 prodrug Substances 0.000 claims description 21
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 19
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 17
- 206010012601 diabetes mellitus Diseases 0.000 claims description 17
- 239000002207 metabolite Substances 0.000 claims description 17
- 102000051325 Glucagon Human genes 0.000 claims description 13
- 108060003199 Glucagon Proteins 0.000 claims description 13
- 239000002329 esterase inhibitor Substances 0.000 claims description 13
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 13
- 229960004666 glucagon Drugs 0.000 claims description 13
- 102100033639 Acetylcholinesterase Human genes 0.000 claims description 12
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 12
- 229940122601 Esterase inhibitor Drugs 0.000 claims description 12
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 12
- 208000030159 metabolic disease Diseases 0.000 claims description 11
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 10
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 claims description 9
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 claims description 9
- 102000018389 Exopeptidases Human genes 0.000 claims description 7
- 108010091443 Exopeptidases Proteins 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 229940127219 anticoagulant drug Drugs 0.000 claims description 5
- 125000004185 ester group Chemical group 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 4
- 208000016097 disease of metabolism Diseases 0.000 claims description 4
- 108010049869 gastric inhibitory polypeptide (1-42) Proteins 0.000 claims description 4
- 239000004033 plastic Substances 0.000 claims description 4
- 229920003023 plastic Polymers 0.000 claims description 4
- 102000012479 Serine Proteases Human genes 0.000 claims description 3
- 108010022999 Serine Proteases Proteins 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- QXGGCRMRWONSSB-UHFFFAOYSA-N 1-[ethoxy(fluoro)phosphoryl]octane Chemical compound CCCCCCCCP(F)(=O)OCC QXGGCRMRWONSSB-UHFFFAOYSA-N 0.000 claims description 2
- BYUCSFWXCMTYOI-ZRDIBKRKSA-N Bromoenol lactone Chemical compound O=C1OC(=C/Br)/CCC1C1=CC=CC2=CC=CC=C12 BYUCSFWXCMTYOI-ZRDIBKRKSA-N 0.000 claims description 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims description 2
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- SFRALHFBKRAJPW-UHFFFAOYSA-N IDFP Chemical compound CCCCCCCCCCCCP(F)(=O)OC(C)C SFRALHFBKRAJPW-UHFFFAOYSA-N 0.000 claims description 2
- KWKZCGMJGHHOKJ-ZKWNWVNESA-N Methyl Arachidonyl Fluorophosphonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCP(F)(=O)OC KWKZCGMJGHHOKJ-ZKWNWVNESA-N 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 2
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims 2
- 101710118538 Protease Proteins 0.000 claims 1
- 229940127090 anticoagulant agent Drugs 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- BGHSOEHUOOAYMY-JTZMCQEISA-N ghrelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C1=CC=CC=C1 BGHSOEHUOOAYMY-JTZMCQEISA-N 0.000 description 31
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 23
- 229960001685 tacrine Drugs 0.000 description 21
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 210000002381 plasma Anatomy 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 102000035195 Peptidases Human genes 0.000 description 14
- 108091005804 Peptidases Proteins 0.000 description 14
- 239000004365 Protease Substances 0.000 description 14
- HNVKMEOEBANRAT-ZKWNWVNESA-N (5z,8z,11z,14z)-1-[fluoro(methoxy)phosphoryl]oxyicosa-5,8,11,14-tetraene Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCOP(F)(=O)OC HNVKMEOEBANRAT-ZKWNWVNESA-N 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 11
- 229940022698 acetylcholinesterase Drugs 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 102100040918 Pro-glucagon Human genes 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 108090000371 Esterases Proteins 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 7
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 229940124596 AChE inhibitor Drugs 0.000 description 6
- 102100040280 Acyl-protein thioesterase 1 Human genes 0.000 description 6
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 6
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 101710132086 Acyl-protein thioesterase 1 Proteins 0.000 description 5
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 5
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 5
- 102100032404 Cholinesterase Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229950009811 ubenimex Drugs 0.000 description 5
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 4
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 4
- 108010052968 leupeptin Proteins 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 239000003001 serine protease inhibitor Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- MGHMJPKLGSHAKY-UHFFFAOYSA-N 1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=CC=C2C=C3C(O)CCCC3=NC2=C1 MGHMJPKLGSHAKY-UHFFFAOYSA-N 0.000 description 3
- KETQAJRQOHHATG-UHFFFAOYSA-N 1,2-naphthoquinone Chemical compound C1=CC=C2C(=O)C(=O)C=CC2=C1 KETQAJRQOHHATG-UHFFFAOYSA-N 0.000 description 3
- QDFHIWZDZCQXJR-UHFFFAOYSA-N 2-[bis[3-(1,2,3,4-tetrahydroacridin-9-ylamino)propyl]amino]ethanol Chemical compound C1=CC=C2C(NCCCN(CCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)CCO)=C(CCCC3)C3=NC2=C1 QDFHIWZDZCQXJR-UHFFFAOYSA-N 0.000 description 3
- IPFDTWHBEBJTLE-UHFFFAOYSA-N 2h-acridin-1-one Chemical compound C1=CC=C2C=C3C(=O)CC=CC3=NC2=C1 IPFDTWHBEBJTLE-UHFFFAOYSA-N 0.000 description 3
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 3
- 108010051152 Carboxylesterase Proteins 0.000 description 3
- 102000013392 Carboxylesterase Human genes 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- 229940122344 Peptidase inhibitor Drugs 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 229940122055 Serine protease inhibitor Drugs 0.000 description 3
- 101710102218 Serine protease inhibitor Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 108700013122 acyl-ghrelin Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229960004203 carnitine Drugs 0.000 description 3
- YSJSSHIVMXYVNW-ZVWHLABXSA-N chembl1684446 Chemical compound Cl.N1=C2C=C(Cl)C=CC2=C(N)C2=C1C[C@H]1C=C(CC)C[C@@H]2C1 YSJSSHIVMXYVNW-ZVWHLABXSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000020176 deacylation Effects 0.000 description 3
- 238000005947 deacylation reaction Methods 0.000 description 3
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000002753 trypsin inhibitor Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- SPTZDSUPALKLJK-UHFFFAOYSA-N 9-[(4-fluorophenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC(F)=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 SPTZDSUPALKLJK-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108090000322 Cholinesterases Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 2
- QFAADIRHLBXJJS-ZAZJUGBXSA-N amastatin Chemical compound CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O QFAADIRHLBXJJS-ZAZJUGBXSA-N 0.000 description 2
- 108010052590 amastatin Proteins 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- ITZOKHKOFJOBFS-UHFFFAOYSA-N bis(7)-tacrine Chemical compound C1=CC=C2C(NCCCCCCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)=C(CCCC3)C3=NC2=C1 ITZOKHKOFJOBFS-UHFFFAOYSA-N 0.000 description 2
- 125000006309 butyl amino group Chemical group 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229940048961 cholinesterase Drugs 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 108010051768 des-n-octanoyl ghrelin Proteins 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical class CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 125000001207 fluorophenyl group Chemical group 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- JFRYPNLJVPMTIS-UHFFFAOYSA-N n'-ethyl-n-(1,2,3,4-tetrahydroacridin-9-yl)-n'-[3-(1,2,3,4-tetrahydroacridin-9-ylamino)propyl]propane-1,3-diamine Chemical compound C1=CC=C2C(NCCCN(CCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)CC)=C(CCCC3)C3=NC2=C1 JFRYPNLJVPMTIS-UHFFFAOYSA-N 0.000 description 2
- ZIDVXYDWJIVBSC-UHFFFAOYSA-N n,n'-bis(1,2,3,4-tetrahydroacridin-9-yl)octane-1,8-diamine Chemical compound C1=CC=C2C(NCCCCCCCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)=C(CCCC3)C3=NC2=C1 ZIDVXYDWJIVBSC-UHFFFAOYSA-N 0.000 description 2
- NECDJQNRWSICKG-UHFFFAOYSA-N n,n'-bis(1,2,3,4-tetrahydroacridin-9-yl)pentane-1,5-diamine Chemical compound C1=CC=C2C(NCCCCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)=C(CCCC3)C3=NC2=C1 NECDJQNRWSICKG-UHFFFAOYSA-N 0.000 description 2
- COEYCPFFRLYNSC-UHFFFAOYSA-N n-[8-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)octyl]-1,2,3,4-tetrahydroacridin-9-amine Chemical compound C1=CC=C2C(NCCCCCCCCSC=3C4=CC=CC=C4N=C4CCCCC4=3)=C(CCCC3)C3=NC2=C1 COEYCPFFRLYNSC-UHFFFAOYSA-N 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229950000964 pepstatin Drugs 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- CDOZDBSBBXSXLB-UHFFFAOYSA-N profenamine Chemical compound C1=CC=C2N(CC(C)N(CC)CC)C3=CC=CC=C3SC2=C1 CDOZDBSBBXSXLB-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 2
- 229940032712 succinylcholine Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- ZRJBHWIHUMBLCN-MEBBXXQBSA-N (-)-Huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-MEBBXXQBSA-N 0.000 description 1
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 1
- QMGHHBHPDDAGGO-IIWOMYBWSA-N (2S,4R)-1-[(2S)-2-[[2-[3-[4-[3-[4-[[5-bromo-4-[3-[cyclobutanecarbonyl(methyl)amino]propylamino]pyrimidin-2-yl]amino]phenoxy]propoxy]butoxy]propoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide Chemical compound CN(CCCNC1=NC(NC2=CC=C(OCCCOCCCCOCCCOCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C=C3)C3=C(C)N=CS3)C(C)(C)C)C=C2)=NC=C1Br)C(=O)C1CCC1 QMGHHBHPDDAGGO-IIWOMYBWSA-N 0.000 description 1
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- IJWCGVPEDDQUDE-YGJAXBLXSA-N (2s)-2-[[(1s)-2-[[(2s)-5-amino-1,5-dioxo-1-[[(2s)-1-oxopropan-2-yl]amino]pentan-2-yl]amino]-1-[(6s)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-2-oxoethyl]carbamoylamino]-4-methylpentanoic acid Chemical compound O=C[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H]1CCN=C(N)N1 IJWCGVPEDDQUDE-YGJAXBLXSA-N 0.000 description 1
- PMHUSCHKTSTQEP-UHFFFAOYSA-N (4-carbamimidoylphenyl)methanesulfonyl fluoride Chemical compound NC(=N)C1=CC=C(CS(F)(=O)=O)C=C1 PMHUSCHKTSTQEP-UHFFFAOYSA-N 0.000 description 1
- 229940105324 1,2-naphthoquinone Drugs 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical group CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- WDJVLQGAMOVSFM-UHFFFAOYSA-N 1-amino-9-(4,4-diphenylbutyl)-3,4-dihydro-2H-acridin-1-ol Chemical compound C1(=CC=CC=C1)C(CCCC=1C2=CC=CC=C2N=C2CCCC(C12)(O)N)C1=CC=CC=C1 WDJVLQGAMOVSFM-UHFFFAOYSA-N 0.000 description 1
- UPMXSZJSGSKECM-UHFFFAOYSA-N 1-amino-9-[[2-(trifluoromethyl)phenyl]methyl]-3,4-dihydro-2H-acridin-1-ol Chemical compound FC(C1=C(CC=2C3=CC=CC=C3N=C3CCCC(C23)(O)N)C=CC=C1)(F)F UPMXSZJSGSKECM-UHFFFAOYSA-N 0.000 description 1
- JDKWKFMWRPYWPM-UHFFFAOYSA-N 2-(ethylamino)-3,4-dihydro-2H-acridin-1-one Chemical compound CCNC1CCc2nc3ccccc3cc2C1=O JDKWKFMWRPYWPM-UHFFFAOYSA-N 0.000 description 1
- ROZRQBDDTKLZQC-UHFFFAOYSA-N 2-(trifluoromethyl)-2H-acridin-1-one Chemical compound FC(F)(F)C1C(C2=CC3=CC=CC=C3N=C2C=C1)=O ROZRQBDDTKLZQC-UHFFFAOYSA-N 0.000 description 1
- SDNYTAYICBFYFH-MAHYXTOZSA-N 2-[[(2s)-5-(diaminomethylideneamino)-1-[[(2s)-1-[[5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamoylamino]-3-phenylpropanoic acid Chemical compound NC(N)=NCCCC(C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-MAHYXTOZSA-N 0.000 description 1
- NWHLDTDOCDBSFO-UHFFFAOYSA-N 2-amino-9-(4,4-diphenylbutyl)-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)C(N)CCC2=NC2=CC=CC=C2C=1CCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NWHLDTDOCDBSFO-UHFFFAOYSA-N 0.000 description 1
- HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical compound NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 description 1
- UYBONVMPKQXUQU-UHFFFAOYSA-N 3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC=C2C=C3C(=O)CCCC3=NC2=C1 UYBONVMPKQXUQU-UHFFFAOYSA-N 0.000 description 1
- FXIXTBXOXHQRSQ-UHFFFAOYSA-N 3-amino-4-chloro-2-(3-oxocyclohexen-1-yl)benzonitrile Chemical compound ClC1=C(C(=C(C#N)C=C1)C1=CC(CCC1)=O)N FXIXTBXOXHQRSQ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- ISUJWDYWYFLQFP-UHFFFAOYSA-N 6,8-dichloro-1,2,3,4-tetrahydroacridin-9-amine Chemical compound ClC1=CC(Cl)=C2C(N)=C(CCCC3)C3=NC2=C1 ISUJWDYWYFLQFP-UHFFFAOYSA-N 0.000 description 1
- TVJGNZTYBOUSAY-UHFFFAOYSA-N 6,8-dichloro-n-[7-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)heptyl]-1,2,3,4-tetrahydroacridin-9-amine Chemical compound C1CCCC2=NC3=CC(Cl)=CC(Cl)=C3C(NCCCCCCCSC=3C4=CC=CC=C4N=C4CCCCC4=3)=C21 TVJGNZTYBOUSAY-UHFFFAOYSA-N 0.000 description 1
- BWUMQCFIOGGVAH-UHFFFAOYSA-N 6-chloro-2-methoxyacridin-9-amine Chemical compound C1=C(Cl)C=CC2=C(N)C3=CC(OC)=CC=C3N=C21.C1=C(Cl)C=CC2=C(N)C3=CC(OC)=CC=C3N=C21 BWUMQCFIOGGVAH-UHFFFAOYSA-N 0.000 description 1
- LSWZHJUDTDSZPN-UHFFFAOYSA-N 6-fluoro-9-[[2-(trifluoromethyl)phenyl]methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC(F)=CC=C2C=1NCC1=CC=CC=C1C(F)(F)F LSWZHJUDTDSZPN-UHFFFAOYSA-N 0.000 description 1
- OZCGCAPFASUXEH-UHFFFAOYSA-N 6-fluoro-9-[[2-(trifluoromethyl)phenyl]methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC(F)=CC=C2C=1NCC1=CC=CC=C1C(F)(F)F OZCGCAPFASUXEH-UHFFFAOYSA-N 0.000 description 1
- UYKKLMHSHHDZGW-UHFFFAOYSA-N 7-ethoxyacridine-3,9-diamine Chemical compound C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 UYKKLMHSHHDZGW-UHFFFAOYSA-N 0.000 description 1
- KLCMFEHXVCLFMX-UHFFFAOYSA-N 9-(2-phenylethylamino)-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC=CC=C2C=1NCCC1=CC=CC=C1 KLCMFEHXVCLFMX-UHFFFAOYSA-N 0.000 description 1
- OMPBZSLBVKDSJL-UHFFFAOYSA-N 9-(3-phenoxypropylamino)-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCCCOC1=CC=CC=C1 OMPBZSLBVKDSJL-UHFFFAOYSA-N 0.000 description 1
- IHSFBFHFFMJLSM-UHFFFAOYSA-N 9-(3-phenoxypropylamino)-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC=CC=C2C=1NCCCOC1=CC=CC=C1 IHSFBFHFFMJLSM-UHFFFAOYSA-N 0.000 description 1
- YJHBLVYLSYRPFV-UHFFFAOYSA-N 9-(4,4-diphenylbutylamino)-6-(trifluoromethyl)-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC(C(F)(F)F)=CC=C2C=1NCCCC(C=1C=CC=CC=1)C1=CC=CC=C1 YJHBLVYLSYRPFV-UHFFFAOYSA-N 0.000 description 1
- HERUZAOANPGYSY-UHFFFAOYSA-N 9-(benzylamino)-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CC=C1 HERUZAOANPGYSY-UHFFFAOYSA-N 0.000 description 1
- UFBJNPUZMUQXFV-UHFFFAOYSA-N 9-(benzylamino)-6-chloro-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC(Cl)=CC=C2C=1NCC1=CC=CC=C1 UFBJNPUZMUQXFV-UHFFFAOYSA-N 0.000 description 1
- LWGKFQQSAQUNMS-UHFFFAOYSA-N 9-(benzylamino)-6-chloro-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC(Cl)=CC=C2C=1NCC1=CC=CC=C1 LWGKFQQSAQUNMS-UHFFFAOYSA-N 0.000 description 1
- PRBCPEIUILMRLL-UHFFFAOYSA-N 9-(benzylamino)-6-fluoro-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC(F)=CC=C2C=1NCC1=CC=CC=C1 PRBCPEIUILMRLL-UHFFFAOYSA-N 0.000 description 1
- PFNNWRPESNOURZ-UHFFFAOYSA-N 9-(benzylamino)-6-methyl-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC(C)=CC=C2C=1NCC1=CC=CC=C1 PFNNWRPESNOURZ-UHFFFAOYSA-N 0.000 description 1
- WETURUQUTKXZKR-UHFFFAOYSA-N 9-(methylamino)-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=CC=C2C(NC)=C(C(O)CCC3)C3=NC2=C1 WETURUQUTKXZKR-UHFFFAOYSA-N 0.000 description 1
- YHPKDQOHCJWZKV-UHFFFAOYSA-N 9-(methylamino)-7-nitro-3,4-dihydro-2h-acridin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(NC)=C(C(=O)CCC3)C3=NC2=C1 YHPKDQOHCJWZKV-UHFFFAOYSA-N 0.000 description 1
- XRKIMANYLDOPAR-UHFFFAOYSA-N 9-(propylamino)-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=CC=C2C(NCCC)=C(C(O)CCC3)C3=NC2=C1 XRKIMANYLDOPAR-UHFFFAOYSA-N 0.000 description 1
- HVYUZYLNNWIMHS-UHFFFAOYSA-N 9-(thiophen-2-ylmethylamino)-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CS1 HVYUZYLNNWIMHS-UHFFFAOYSA-N 0.000 description 1
- OANFKRNIOKICTD-UHFFFAOYSA-N 9-(thiophen-2-ylmethylamino)-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CS1 OANFKRNIOKICTD-UHFFFAOYSA-N 0.000 description 1
- SHMLXHJDPNXDDR-UHFFFAOYSA-N 9-[(2,3,4,5,6-pentafluorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=C(F)C(F)=C(F)C(F)=C1F SHMLXHJDPNXDDR-UHFFFAOYSA-N 0.000 description 1
- XFWKEFHMUGMJLM-UHFFFAOYSA-N 9-[(2-chlorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CC=C1Cl XFWKEFHMUGMJLM-UHFFFAOYSA-N 0.000 description 1
- BEQRYHCXYAFPRU-UHFFFAOYSA-N 9-[(2-chlorophenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound ClC1=CC=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 BEQRYHCXYAFPRU-UHFFFAOYSA-N 0.000 description 1
- CITBUWNJIQLRPB-UHFFFAOYSA-N 9-[(2-fluorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CC=C1F CITBUWNJIQLRPB-UHFFFAOYSA-N 0.000 description 1
- FXEQIZHVYQIOKN-UHFFFAOYSA-N 9-[(2-fluorophenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound FC1=CC=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 FXEQIZHVYQIOKN-UHFFFAOYSA-N 0.000 description 1
- RBRKTJWKILJWSY-UHFFFAOYSA-N 9-[(2-methoxyphenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound COC1=CC=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 RBRKTJWKILJWSY-UHFFFAOYSA-N 0.000 description 1
- UINYYDDIQJCNLY-UHFFFAOYSA-N 9-[(2-methylphenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound CC1=CC=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 UINYYDDIQJCNLY-UHFFFAOYSA-N 0.000 description 1
- PAKRGUABUWIYQH-UHFFFAOYSA-N 9-[(3-chlorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CC(Cl)=C1 PAKRGUABUWIYQH-UHFFFAOYSA-N 0.000 description 1
- OYECSEBZWOFEHH-UHFFFAOYSA-N 9-[(3-fluorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CC(F)=C1 OYECSEBZWOFEHH-UHFFFAOYSA-N 0.000 description 1
- FGIQFWDLUQLRSY-UHFFFAOYSA-N 9-[(3-fluorophenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound FC1=CC=CC(CNC=2C3=CC=CC=C3N=C3CCCC(=O)C3=2)=C1 FGIQFWDLUQLRSY-UHFFFAOYSA-N 0.000 description 1
- IHJHKGXTVXBZTN-UHFFFAOYSA-N 9-[(3-methoxyphenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound COC1=CC=CC(CNC=2C3=CC=CC=C3N=C3CCCC(=O)C3=2)=C1 IHJHKGXTVXBZTN-UHFFFAOYSA-N 0.000 description 1
- VQTIDCIBXATCPW-UHFFFAOYSA-N 9-[(3-methylphenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound CC1=CC=CC(CNC=2C3=CC=CC=C3N=C3CCCC(O)C3=2)=C1 VQTIDCIBXATCPW-UHFFFAOYSA-N 0.000 description 1
- HEKGBDCRHYILPL-UHFFFAOYSA-N 9-[(4-chlorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=C(Cl)C=C1 HEKGBDCRHYILPL-UHFFFAOYSA-N 0.000 description 1
- JUCJXAPYPXKKTH-UHFFFAOYSA-N 9-[(4-chlorophenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC(Cl)=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 JUCJXAPYPXKKTH-UHFFFAOYSA-N 0.000 description 1
- APOMRWXYQSHYMK-UHFFFAOYSA-N 9-[(4-fluorophenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=C(F)C=C1 APOMRWXYQSHYMK-UHFFFAOYSA-N 0.000 description 1
- GKQCJUSPLSEUKC-UHFFFAOYSA-N 9-[(4-methoxyphenyl)methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=CC(OC)=CC=C1CNC1=C(C(O)CCC2)C2=NC2=CC=CC=C12 GKQCJUSPLSEUKC-UHFFFAOYSA-N 0.000 description 1
- YCPZBHOZTZSCDZ-UHFFFAOYSA-N 9-[(4-methoxyphenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC(OC)=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 YCPZBHOZTZSCDZ-UHFFFAOYSA-N 0.000 description 1
- AFOVBHWSLBYRMT-UHFFFAOYSA-N 9-[(4-methylphenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC(C)=CC=C1CNC1=C(C(=O)CCC2)C2=NC2=CC=CC=C12 AFOVBHWSLBYRMT-UHFFFAOYSA-N 0.000 description 1
- ONAWRDUAMMKGLA-UHFFFAOYSA-N 9-[(4-phenylmethoxyphenyl)methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound C=12C(=O)CCCC2=NC2=CC=CC=C2C=1NCC(C=C1)=CC=C1OCC1=CC=CC=C1 ONAWRDUAMMKGLA-UHFFFAOYSA-N 0.000 description 1
- RMJNBGWBTQUGAS-UHFFFAOYSA-N 9-[4,4-bis(3-fluorophenyl)butylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCCCC(C=1C=C(F)C=CC=1)C1=CC=CC(F)=C1 RMJNBGWBTQUGAS-UHFFFAOYSA-N 0.000 description 1
- FJBDEUGVWSVISL-UHFFFAOYSA-N 9-[4,4-bis(3-fluorophenyl)butylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound FC1=CC=CC(C(CCCNC=2C3=CC=CC=C3N=C3CCCC(=O)C3=2)C=2C=C(F)C=CC=2)=C1 FJBDEUGVWSVISL-UHFFFAOYSA-N 0.000 description 1
- BCLCATIAJDFAPY-UHFFFAOYSA-N 9-[[3-(trifluoromethyl)phenyl]methylamino]-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C=12C(O)CCCC2=NC2=CC=CC=C2C=1NCC1=CC=CC(C(F)(F)F)=C1 BCLCATIAJDFAPY-UHFFFAOYSA-N 0.000 description 1
- UFRJCXVTCQWAIU-UHFFFAOYSA-N 9-[[3-(trifluoromethyl)phenyl]methylamino]-3,4-dihydro-2h-acridin-1-one Chemical compound FC(F)(F)C1=CC=CC(CNC=2C3=CC=CC=C3N=C3CCCC(=O)C3=2)=C1 UFRJCXVTCQWAIU-UHFFFAOYSA-N 0.000 description 1
- HLVVITIHAZBPKB-UHFFFAOYSA-N 9-amino-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=CC=C2C(N)=C(C(O)CCC3)C3=NC2=C1 HLVVITIHAZBPKB-UHFFFAOYSA-N 0.000 description 1
- BAXFTNIJRPIJEU-UHFFFAOYSA-N 9-amino-1-methyl-3,4-dihydro-2h-acridin-1-ol Chemical compound C1=CC=C2C(N)=C3C(C)(O)CCCC3=NC2=C1 BAXFTNIJRPIJEU-UHFFFAOYSA-N 0.000 description 1
- LKWKQKKNFMIICA-UHFFFAOYSA-N 9-amino-2,3-dihydrocyclopenta[b]quinolin-1-one Chemical compound C1=CC=C2C(N)=C(C(=O)CC3)C3=NC2=C1 LKWKQKKNFMIICA-UHFFFAOYSA-N 0.000 description 1
- XNJYRASUSQYMTL-UHFFFAOYSA-N 9-amino-2-methylidene-3,4-dihydroacridin-1-one Chemical compound C1=CC=C2C(N)=C(C(=O)C(=C)CC3)C3=NC2=C1 XNJYRASUSQYMTL-UHFFFAOYSA-N 0.000 description 1
- JUSJJSHTMCPMOX-UHFFFAOYSA-N 9-amino-3,4-dihydro-2h-acridin-1-one Chemical compound C1=CC=C2C(N)=C(C(=O)CCC3)C3=NC2=C1 JUSJJSHTMCPMOX-UHFFFAOYSA-N 0.000 description 1
- ZHFXMERFRYSFFB-UHFFFAOYSA-N 9-amino-6-(trifluoromethyl)-1,2,3,4-tetrahydroacridin-1-ol Chemical compound FC(F)(F)C1=CC=C2C(N)=C(C(O)CCC3)C3=NC2=C1 ZHFXMERFRYSFFB-UHFFFAOYSA-N 0.000 description 1
- LHBQKFLAPXCANH-UHFFFAOYSA-N 9-amino-6-chloro-1,2,3,4-tetrahydroacridin-1-ol Chemical compound ClC1=CC=C2C(N)=C(C(O)CCC3)C3=NC2=C1 LHBQKFLAPXCANH-UHFFFAOYSA-N 0.000 description 1
- BQODEXMWLQQVQQ-UHFFFAOYSA-N 9-amino-6-fluoro-3,4-dihydro-2h-acridin-1-one Chemical compound FC1=CC=C2C(N)=C(C(=O)CCC3)C3=NC2=C1 BQODEXMWLQQVQQ-UHFFFAOYSA-N 0.000 description 1
- OALAJFHZGANODE-UHFFFAOYSA-N 9-amino-6-methoxy-1,2,3,4-tetrahydroacridin-1-ol Chemical compound OC1CCCC2=NC3=CC(OC)=CC=C3C(N)=C21 OALAJFHZGANODE-UHFFFAOYSA-N 0.000 description 1
- WMLMRDSLHWHTTP-UHFFFAOYSA-N 9-amino-6-methoxy-3,4-dihydro-2h-acridin-1-one Chemical compound O=C1CCCC2=NC3=CC(OC)=CC=C3C(N)=C21 WMLMRDSLHWHTTP-UHFFFAOYSA-N 0.000 description 1
- UVGIDXFDFPOSEE-UHFFFAOYSA-N 9-amino-6-methyl-3,4-dihydro-2h-acridin-1-one Chemical compound O=C1CCCC2=NC3=CC(C)=CC=C3C(N)=C21 UVGIDXFDFPOSEE-UHFFFAOYSA-N 0.000 description 1
- SJMIUHDBFGTYAA-UHFFFAOYSA-N 9-amino-7-chloro-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=C(Cl)C=C2C(N)=C(C(O)CCC3)C3=NC2=C1 SJMIUHDBFGTYAA-UHFFFAOYSA-N 0.000 description 1
- NGGNNYCJIOMJBD-UHFFFAOYSA-N 9-amino-7-nitro-3,4-dihydro-2h-acridin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(N)=C(C(=O)CCC3)C3=NC2=C1 NGGNNYCJIOMJBD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108050009514 Antigen peptide transporter 1 Proteins 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- MYTVVMGUDBRCDJ-UHFFFAOYSA-N Bufencarb Chemical compound CCCC(C)C1=CC=CC(OC(=O)NC)=C1.CCC(CC)C1=CC=CC(OC(=O)NC)=C1 MYTVVMGUDBRCDJ-UHFFFAOYSA-N 0.000 description 1
- FYCMCASHXQJACM-UHFFFAOYSA-N CN(CCC=1C2=CC=CC=C2N=C2CCC(C(C=12)=O)N)C Chemical compound CN(CCC=1C2=CC=CC=C2N=C2CCC(C(C=12)=O)N)C FYCMCASHXQJACM-UHFFFAOYSA-N 0.000 description 1
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N Carbendazim Natural products C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102100036806 Carboxylesterase 5A Human genes 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- ULBXWWGWDPVHAO-UHFFFAOYSA-N Chlorbufam Chemical compound C#CC(C)OC(=O)NC1=CC=CC(Cl)=C1 ULBXWWGWDPVHAO-UHFFFAOYSA-N 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000005947 Dimethoate Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 description 1
- IJWCGVPEDDQUDE-UHFFFAOYSA-N Elastatinal Natural products O=CC(C)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)NC(CC(C)C)C(O)=O)C1CCN=C(N)N1 IJWCGVPEDDQUDE-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 229940124143 Endopeptidase inhibitor Drugs 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 241001090156 Huperzia serrata Species 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- 241000195947 Lycopodium Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NFAXDNGDYPREOQ-UHFFFAOYSA-N O=C1CC=CC2=NC3=CC(F)=CC=C3C=C21 Chemical compound O=C1CC=CC2=NC3=CC(F)=CC=C3C=C21 NFAXDNGDYPREOQ-UHFFFAOYSA-N 0.000 description 1
- BEKQPDFPPJFVJP-AHSQCEKMSA-N Onchidal Chemical compound CC(=O)O\C=C\C(\C=O)=C/CC1C(=C)CCCC1(C)C BEKQPDFPPJFVJP-AHSQCEKMSA-N 0.000 description 1
- JLVLVOITZSLHPU-UHFFFAOYSA-N Onchidal Natural products CC(=O)OC(=CC(=C/CC1C(=C)CCCC1(C)C)C=O)C JLVLVOITZSLHPU-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000005821 Propamocarb Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
- ISRUGXGCCGIOQO-UHFFFAOYSA-N Rhoden Chemical compound CNC(=O)OC1=CC=CC=C1OC(C)C ISRUGXGCCGIOQO-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101710097834 Thiol protease Proteins 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- PJVJTCIRVMBVIA-JTQLQIEISA-N [dimethylamino(ethoxy)phosphoryl]formonitrile Chemical compound CCO[P@@](=O)(C#N)N(C)C PJVJTCIRVMBVIA-JTQLQIEISA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- XIVOUNPJCNJBPR-UHFFFAOYSA-N acridin-1-ol Chemical compound C1=CC=C2C=C3C(O)=CC=CC3=NC2=C1 XIVOUNPJCNJBPR-UHFFFAOYSA-N 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- QGLZXHRNAYXIBU-WEVVVXLNSA-N aldicarb Chemical compound CNC(=O)O\N=C\C(C)(C)SC QGLZXHRNAYXIBU-WEVVVXLNSA-N 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- 229960000451 ambenonium Drugs 0.000 description 1
- OMHBPUNFVFNHJK-UHFFFAOYSA-P ambenonium Chemical compound C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl OMHBPUNFVFNHJK-UHFFFAOYSA-P 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- XEGGRYVFLWGFHI-UHFFFAOYSA-N bendiocarb Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)O2 XEGGRYVFLWGFHI-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 239000013063 calibration and quality control sample Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 229960005286 carbaryl Drugs 0.000 description 1
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
- JNPZQRQPIHJYNM-UHFFFAOYSA-N carbendazim Chemical compound C1=C[CH]C2=NC(NC(=O)OC)=NC2=C1 JNPZQRQPIHJYNM-UHFFFAOYSA-N 0.000 description 1
- 239000006013 carbendazim Substances 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 101150005346 coaBC gene Proteins 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical class C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- 108010054812 diprotin A Proteins 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229960003748 edrophonium Drugs 0.000 description 1
- 108010039262 elastatinal Proteins 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- UXALQTVODWAKFT-UHFFFAOYSA-N heptan-2-one;hydrochloride Chemical compound Cl.CCCCCC(C)=O UXALQTVODWAKFT-UHFFFAOYSA-N 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000008587 i-STAT CHEM8+ Cartridge Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940127560 insulin pen Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- ZFLWDHHVRRZMEI-UHFFFAOYSA-N methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C([N+]([O-])=O)C1C1=CC=CC=C1C(F)(F)F ZFLWDHHVRRZMEI-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001952 metrifonate Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- YXYXCYQIHJLUHU-UHFFFAOYSA-N n'-(6,8-dichloro-1,2,3,4-tetrahydroacridin-9-yl)-n-(1,2,3,4-tetrahydroacridin-9-yl)heptane-1,7-diamine Chemical compound C1CCCC2=NC3=CC(Cl)=CC(Cl)=C3C(NCCCCCCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)=C21 YXYXCYQIHJLUHU-UHFFFAOYSA-N 0.000 description 1
- IIQODJRESHGVGO-UHFFFAOYSA-N n'-methyl-n-(1,2,3,4-tetrahydroacridin-9-yl)-n'-[3-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)propyl]propane-1,3-diamine Chemical compound C1=CC=C2C(SCCCN(CCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)C)=C(CCCC3)C3=NC2=C1 IIQODJRESHGVGO-UHFFFAOYSA-N 0.000 description 1
- BCRWNRSCYSXXGB-UHFFFAOYSA-N n'-prop-2-enyl-n-(1,2,3,4-tetrahydroacridin-9-yl)-n'-[3-(1,2,3,4-tetrahydroacridin-9-ylamino)propyl]propane-1,3-diamine Chemical compound C1=CC=C2C(NCCCN(CCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)CC=C)=C(CCCC3)C3=NC2=C1 BCRWNRSCYSXXGB-UHFFFAOYSA-N 0.000 description 1
- AXLKXPGGRMASKW-UHFFFAOYSA-N n,n'-bis(6,8-dichloro-1,2,3,4-tetrahydroacridin-9-yl)heptane-1,7-diamine Chemical compound C1CCCC2=NC3=CC(Cl)=CC(Cl)=C3C(NCCCCCCCNC=3C4=C(Cl)C=C(Cl)C=C4N=C4CCCCC4=3)=C21 AXLKXPGGRMASKW-UHFFFAOYSA-N 0.000 description 1
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
- TWECJTVNEQDUIG-UHFFFAOYSA-N n-[3-(1,2,3,4-tetrahydroacridin-9-ylamino)propyl]-n-[3-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)propyl]acetamide Chemical compound C1=CC=C2C(SCCCN(CCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)C(=O)C)=C(CCCC3)C3=NC2=C1 TWECJTVNEQDUIG-UHFFFAOYSA-N 0.000 description 1
- WMLGPNPGGGQPET-UHFFFAOYSA-N n-[3-(1,2,3,4-tetrahydroacridin-9-ylamino)propyl]-n-[4-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)butyl]acetamide Chemical compound C1=CC=C2C(NCCCN(CCCCSC=3C4=CC=CC=C4N=C4CCCCC4=3)C(=O)C)=C(CCCC3)C3=NC2=C1 WMLGPNPGGGQPET-UHFFFAOYSA-N 0.000 description 1
- IADLMALHTDAHCP-UHFFFAOYSA-N n-[6-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)hexyl]-1,2,3,4-tetrahydroacridin-9-amine Chemical compound C1=CC=C2C(NCCCCCCSC=3C4=CC=CC=C4N=C4CCCCC4=3)=C(CCCC3)C3=NC2=C1 IADLMALHTDAHCP-UHFFFAOYSA-N 0.000 description 1
- QRIQNQYNWBQHLY-UHFFFAOYSA-N n-[7-(1,2,3,4-tetrahydroacridin-9-ylsulfanyl)heptyl]-1,2,3,4-tetrahydroacridin-9-amine Chemical compound C1=CC=C2C(SCCCCCCCNC=3C4=CC=CC=C4N=C4CCCCC4=3)=C(CCCC3)C3=NC2=C1 QRIQNQYNWBQHLY-UHFFFAOYSA-N 0.000 description 1
- LEWUCBWUGAIBAD-UHFFFAOYSA-N n-[8-(1,2,3,4-tetrahydroacridin-9-yl)octyl]-1,2,3,4-tetrahydroacridin-9-amine Chemical compound C1=CC=C2C(NCCCCCCCCC=3C4=CC=CC=C4N=C4CCCCC4=3)=C(CCCC3)C3=NC2=C1 LEWUCBWUGAIBAD-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 108010000416 ovomacroglobulin Proteins 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000007943 positive regulation of appetite Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960002262 profenamine Drugs 0.000 description 1
- WZZLDXDUQPOXNW-UHFFFAOYSA-N propamocarb Chemical compound CCCOC(=O)NCCCN(C)C WZZLDXDUQPOXNW-UHFFFAOYSA-N 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- VXPLXMJHHKHSOA-UHFFFAOYSA-N propham Chemical compound CC(C)OC(=O)NC1=CC=CC=C1 VXPLXMJHHKHSOA-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960002290 pyridostigmine Drugs 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229920006352 transparent thermoplastic Polymers 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/15003—Source of blood for venous or arterial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/14—Devices for taking samples of blood ; Measuring characteristics of blood in vivo, e.g. gas concentration within the blood, pH-value of blood
- A61B5/1405—Devices for taking blood samples
- A61B5/1438—Devices for taking blood samples using pre-evacuated means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150053—Details for enhanced collection of blood or interstitial fluid at the sample site, e.g. by applying compression, heat, vibration, ultrasound, suction or vacuum to tissue; for reduction of pain or discomfort; Skin piercing elements, e.g. blades, needles, lancets or canulas, with adjustable piercing speed
- A61B5/150061—Means for enhancing collection
- A61B5/150099—Means for enhancing collection by negative pressure, other than vacuum extraction into a syringe by pulling on the piston rod or into pre-evacuated tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150251—Collection chamber divided into at least two compartments, e.g. for division of samples
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150351—Caps, stoppers or lids for sealing or closing a blood collection vessel or container, e.g. a test-tube or syringe barrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150389—Hollow piercing elements, e.g. canulas, needles, for piercing the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
- A61B5/154—Devices using pre-evacuated means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Manufacturing & Machinery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449337P | 2011-03-04 | 2011-03-04 | |
| US201161449337P | 2011-03-04 | ||
| PCT/US2012/027391 WO2012121998A1 (en) | 2011-03-04 | 2012-03-02 | Blood collection device containing lysophospholipase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2645022T3 true ES2645022T3 (es) | 2017-12-01 |
Family
ID=45852729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12709440.7T Active ES2645022T3 (es) | 2011-03-04 | 2012-03-02 | Dispositivo de extracción de sangre que contiene inhibidor de lisofosfolipasa |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9459187B2 (enExample) |
| EP (1) | EP2681554B1 (enExample) |
| JP (1) | JP5844826B2 (enExample) |
| CN (2) | CN103477224B (enExample) |
| AU (1) | AU2012225810B2 (enExample) |
| BR (1) | BR112013022662B1 (enExample) |
| CA (1) | CA2828761C (enExample) |
| ES (1) | ES2645022T3 (enExample) |
| MX (1) | MX347230B (enExample) |
| RU (1) | RU2623049C2 (enExample) |
| WO (1) | WO2012121998A1 (enExample) |
| ZA (1) | ZA201306591B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012121998A1 (en) * | 2011-03-04 | 2012-09-13 | Becton, Dickinson And Company | Blood collection device containing lysophospholipase inhibitor |
| EP4350351A3 (en) * | 2015-03-10 | 2024-06-26 | Becton, Dickinson and Company | Biological fluid micro-sample management device |
| US10870115B2 (en) | 2015-08-13 | 2020-12-22 | Dyax Corp. | Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation |
| CN105372109A (zh) * | 2015-12-15 | 2016-03-02 | 苏州药明康德新药开发股份有限公司 | 添加稳定剂的生物基质的制备方法 |
| CN106215993B (zh) * | 2016-07-27 | 2023-07-28 | 上海凯戎医疗科技有限公司 | 一种无菌医用离心管及其用于制备富血小板血浆的制备方法 |
| CN108174843B (zh) * | 2018-01-24 | 2018-11-13 | 广州市进德生物科技有限公司 | 一种胰高血糖素保护剂及其应用 |
| EP3787512B1 (en) * | 2018-05-01 | 2022-03-16 | Becton, Dickinson and Company | Cap with venting plug for biological fluid collection device |
| DE102018218739B3 (de) * | 2018-11-01 | 2020-03-19 | Sarstedt Ag & Co. Kg | Blutentnahmeröhre und Verfahren zur Präparation |
| RU198611U1 (ru) * | 2019-07-10 | 2020-07-21 | Линд Виталий Викторович | Устройство для пробоподготовки крови при проведении жидкостной биопсии с рекомбинантным белком |
| US12434889B2 (en) | 2022-12-09 | 2025-10-07 | Instrumentation Laboratory Company | Sealing systems |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2607773A (en) | 1952-08-19 | Processes for preparing phenthi- | ||
| US337164A (en) | 1886-03-02 | Device for disinfecting | ||
| US4754050A (en) | 1984-10-25 | 1988-06-28 | Hoechst-Roussel Pharmaceuticals, Inc. | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds |
| US5053134A (en) | 1984-12-04 | 1991-10-01 | Becton Dickinson And Company | Lymphocyte collection tube |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| US4833138A (en) | 1987-10-23 | 1989-05-23 | Washington University | Phenothiazinealkaneamines for treatment of neurotoxic injury |
| US5096669A (en) | 1988-09-15 | 1992-03-17 | I-Stat Corporation | Disposable sensing device for real time fluid analysis |
| US5112455A (en) | 1990-07-20 | 1992-05-12 | I Stat Corporation | Method for analytically utilizing microfabricated sensors during wet-up |
| US5821399A (en) | 1993-07-16 | 1998-10-13 | I-Stat Corporation | Automatic test parameters compensation of a real time fluid analysis sensing device |
| US5447440A (en) | 1993-10-28 | 1995-09-05 | I-Stat Corporation | Apparatus for assaying viscosity changes in fluid samples and method of conducting same |
| US5622867A (en) | 1994-10-19 | 1997-04-22 | Lifecell Corporation | Prolonged preservation of blood platelets |
| US5858756A (en) | 1997-04-29 | 1999-01-12 | Incyte Pharmaceuticals, Inc. | Human lysophospholipase |
| US5860937A (en) | 1997-04-30 | 1999-01-19 | Becton, Dickinson & Company | Evacuated sample collection tube with aqueous additive |
| US6143544A (en) | 1997-06-19 | 2000-11-07 | Incyte Pharmaceuticals, Inc. | Human lysophospholipase |
| US6248553B1 (en) | 1998-10-22 | 2001-06-19 | Atairgin Technologies, Inc. | Enzyme method for detecting lysophospholipids and phospholipids and for detecting and correlating conditions associated with altered levels of lysophospholipids |
| US6516953B1 (en) | 1998-12-05 | 2003-02-11 | Becton, Dickinson And Company | Device for separating components of a fluid sample |
| US6406671B1 (en) | 1998-12-05 | 2002-06-18 | Becton, Dickinson And Company | Device and method for separating components of a fluid sample |
| US6497325B1 (en) | 1998-12-05 | 2002-12-24 | Becton Dickinson And Company | Device for separating components of a fluid sample |
| US6750053B1 (en) | 1999-11-15 | 2004-06-15 | I-Stat Corporation | Apparatus and method for assaying coagulation in fluid samples |
| US6409528B1 (en) | 1999-12-06 | 2002-06-25 | Becton, Dickinson And Company | Device and method for collecting, preparation and stabilizing a sample |
| ATE343130T1 (de) * | 1999-12-29 | 2006-11-15 | Perkinelmer Life Sciences Inc | Testtablett, kit und verfahren zum screening von körperflüssigkeiten von neugeborenen durch tandem-massenspektrometrie |
| US7294496B1 (en) | 2000-01-28 | 2007-11-13 | The Regents Of The University Of California | Cloned human lysophospholipase |
| AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| US7419821B2 (en) | 2002-03-05 | 2008-09-02 | I-Stat Corporation | Apparatus and methods for analyte measurement and immunoassay |
| JP2005519134A (ja) * | 2002-03-07 | 2005-06-30 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | ホスホリパーゼａ２が介在する炎症を抑制するための組成物及び方法 |
| WO2003097237A2 (en) | 2002-05-13 | 2003-11-27 | Becton, Dickinson, And Company | Protease inhibitor sample collection system |
| EP1572311A4 (en) | 2002-10-21 | 2007-12-12 | Janssen Pharmaceutica Nv | ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDHYDROLASE |
| US20050124965A1 (en) * | 2003-12-08 | 2005-06-09 | Becton, Dickinson And Company | Phosphatase inhibitor sample collection system |
| RU2356532C2 (ru) | 2007-06-01 | 2009-05-27 | Открытое Акционерное Общество "Отечественные Лекарства" | Фармацевтическая композиция проксодолола с контролируемым высвобождением |
| EP2195034A2 (en) | 2007-09-27 | 2010-06-16 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
| CN101294187B (zh) | 2008-06-06 | 2013-07-31 | 暨南大学 | 一种缓释生物活性多肽的方法与应用 |
| RU2383891C1 (ru) | 2008-07-17 | 2010-03-10 | Владислав Николаевич Ласкавый | Способ качественной предварительной экспресс-диагностики онкологических заболеваний |
| WO2012121998A1 (en) | 2011-03-04 | 2012-09-13 | Becton, Dickinson And Company | Blood collection device containing lysophospholipase inhibitor |
-
2012
- 2012-03-02 WO PCT/US2012/027391 patent/WO2012121998A1/en not_active Ceased
- 2012-03-02 CN CN201280015593.8A patent/CN103477224B/zh active Active
- 2012-03-02 EP EP12709440.7A patent/EP2681554B1/en active Active
- 2012-03-02 BR BR112013022662-5A patent/BR112013022662B1/pt active IP Right Grant
- 2012-03-02 RU RU2013144421A patent/RU2623049C2/ru active
- 2012-03-02 CA CA2828761A patent/CA2828761C/en active Active
- 2012-03-02 MX MX2013010168A patent/MX347230B/es active IP Right Grant
- 2012-03-02 AU AU2012225810A patent/AU2012225810B2/en active Active
- 2012-03-02 US US14/003,033 patent/US9459187B2/en active Active
- 2012-03-02 JP JP2013557765A patent/JP5844826B2/ja active Active
- 2012-03-02 ES ES12709440.7T patent/ES2645022T3/es active Active
- 2012-03-02 CN CN2012200757338U patent/CN203203992U/zh not_active Expired - Lifetime
-
2013
- 2013-09-02 ZA ZA2013/06591A patent/ZA201306591B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012121998A1 (en) | 2012-09-13 |
| JP5844826B2 (ja) | 2016-01-20 |
| US9459187B2 (en) | 2016-10-04 |
| ZA201306591B (en) | 2018-12-19 |
| RU2013144421A (ru) | 2015-04-10 |
| RU2623049C2 (ru) | 2017-06-21 |
| BR112013022662A2 (pt) | 2017-06-27 |
| EP2681554A1 (en) | 2014-01-08 |
| BR112013022662B1 (pt) | 2021-11-23 |
| CA2828761C (en) | 2017-04-04 |
| US20140030754A1 (en) | 2014-01-30 |
| AU2012225810B2 (en) | 2016-11-10 |
| EP2681554B1 (en) | 2017-08-09 |
| MX2013010168A (es) | 2013-10-25 |
| CA2828761A1 (en) | 2012-09-13 |
| JP2014513276A (ja) | 2014-05-29 |
| MX347230B (es) | 2017-04-20 |
| CN103477224A (zh) | 2013-12-25 |
| CN203203992U (zh) | 2013-09-18 |
| CN103477224B (zh) | 2015-12-23 |
| AU2012225810A1 (en) | 2013-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2645022T3 (es) | Dispositivo de extracción de sangre que contiene inhibidor de lisofosfolipasa | |
| US20130209985A1 (en) | Sample collection devices with blood stabilizing agents | |
| JP4496407B2 (ja) | プロテアーゼ阻害剤試料採取システム | |
| EP2696202A1 (en) | Pancreas test method, and pancreas test kit | |
| AU2021254600B2 (en) | Detecting and treating growth hormone deficiency | |
| ES2416493T3 (es) | Sistema de recogida de muestras de inhibidores de fosfatasas | |
| Man et al. | Effect of pentagastrin on histamine output from the stomach in patients with duodenal ulcer. | |
| ES2703512T3 (es) | Agentes que controlan la coagulación y dispositivos que comprenden los mismos | |
| AU619441B2 (en) | Immunoamplifiers and related compositions | |
| US11234969B2 (en) | Detecting and treating growth hormone deficiency | |
| CN109078667A (zh) | 检验科用多功能采血架装置及操作方法 | |
| CN112823793A (zh) | 一种含有多奈哌齐的透皮贴剂及其制备方法 | |
| US20250381353A1 (en) | Nasal cavity sampling methods and apparatus | |
| EP4353829A1 (en) | Method for quantifying phenylalanine in blood, and measurement kit used therefor | |
| Onyeji et al. | Time-dependent variability of chloroquine secretion into human saliva | |
| Hassan et al. | Assessment of Serum Lipid Profile in patients with chronic Hepatitis C | |
| Soares et al. | Determination of captopril by hplctandem mass spectrometry: application in a bioequivalence study | |
| HK1263178B (en) | Detecting and treating growth hormone deficiency |